Bui Dang Minh Tri1, Ly Cong Duy Anh2, Tong Duc Minh3, Bui Khanh Toan4
1 Pham Ngoc Thach University of Medicine
2 Tay Do University
3 Vietnam Military Medical University
4 Tay Nguyen Institute of Hygiene and Epidemiology

Nội dung chính của bài viết

Tóm tắt

Objective: Describing the clinical and subclinical characteristics of the breast cancer
patient treated with Trastuzumab at Thong Nhat hospital.
Subjects and methods: A retrospective study on 48 patients with breast cancer were
treated with Trastuzumab at Thong Nhat hospital.
Results: Mean age: 48.4 ± 3.4 years old. The 45-60 age group accounted for the
largest proportion with 47.92%. Functional symptoms: the proportion of patients who
self-examined the tumor accounted for the highest rate with 64.58%. There were
12.50% of patients with pain symptoms, 10.42% of patients with nipple discharge.
Physical symptoms: tumor in the upper-external quadrant accounted for the largest
percentage with 58.33%. The average size of the tumors was 2.78 ± 1.32 (cm). The
main type of lesions was detected on ultrasound was local lesion with over 77.08%
with an unknown boundary feature (66.67%) and invasive, accounting for 43.75%.
Histopathological type accounted for the highest proportion was the invasive tubular
carcinoma (79.92%). Histological degree accounted for the highest percentage was
degree 2 with 45.83%. Stage II accounted for the highest rate with 39.58%, stage VI
had the lowest rate with 10.42%.
Conclusion: Common age of breast cancer patients was 45 - 60 years old, mainly
the self-examined tumor, common breast tumors were found in the upper-external
quadrant. On ultrasound, mainly the local lesion, the boundary was not clear. The
histopathological type was the invasive tubular carcinoma.

Chi tiết bài viết

Tài liệu tham khảo

[1] Freddie Bray, Jacques Ferlay, Isabelle
Soerjomataram et al., Global Cancer
Statistics 2018: GLOBOCAN Estimates
of Incidence and Mortality Worldwide
for 36 Cancers in 185 Countries. Ca
Cancer J Clin, 2018; 68: 394–424.
[2] Bui Dieu et al., Trends in breast cancer
in Vietnam to 2020. Vietnam Medical
Journal, 2012; 393(1): 127-131.
[3] Fredholm H, Eaker S, Frisell J et al.,
Breast cancer in young women: poor
survival despite intensive treatment. PloS
One, 2009; 4(11): e7695.
[4] Phung Thi Huyen, Evaluation of results of
adjuvant chemotherapy regimens 4AC +
4T combined with trastuzumab on patients
with breast cancer stage II, III with Her 2
neu positive, Doctor of Medicine thesis,
Hanoi Medical University, 2016.
[5] Le Hong Quang, Application of imaging
techniques and biopsy of portal nodes in
assessing axillary lymph node metastasis
in breast cancer patients, Doctor of
Medicine Thesis, Hanoi Medical
University, 2012.
[6] Khouri MG, Douglas PS, Mackey JR et al.,
Cancer therapyinduced cardiac toxicity
in early breast cancer: Addressing the
unresolved issues. Circulation research,
2012; 126: 2749–2763.
[7] Somaira Nowsheen, Aziz K, Park JY et
al., Trastuzumab in Female Breast Cancer
Patients With Reduced Left Ventricular
Ejection Fraction. J Am Heart Assoc,
2018; Aug 7;7(15):e008637
[8] Veronesi U, Viale G, Paganelli G et al.,
Sentinel lymph node biopsy in breast
cancer: ten-year results of a randomized
controlled study. Ann Surg, 2010; 251:
[9] Nguyen Van Thang, Study on the
diagnostic value of mammogram x-ray
combined with ultrasound of the breast.
Journal of Practical Medicine, 2013;